Förderbereich Molekulare Onkologie und Hämatologie

Funding area Molecular Oncology and Haematology

Current research projects

The Molecular Haematology and Oncology group focuses on the development of innovative therapeutic cancer agents.

Research focus

The research of the Molecular Oncology and Haematology Working Group would not be possible without the continuous support of funding institutions, grants, research support from industry and dedicated donors. Current research projects that can be supported include the following:

Ongoing research projects of the working group deal, among other things, with the pathophysiological clarification of multiple myeloma and breast carcinoma. Multiple myeloma (cancer of the bone marrow) is the second most common malignant haematological tumour disease. Mammary carcinoma (breast cancer) is the most common tumour disease in women.

Another focus is the identification of molecular mechanisms that lead to tumour-associated bone diseases. The aim of this research focus is to develop new diagnostics, prognostics and therapeutics.

Health policy relevance of tumour diseases

Currently, about 350,000 people are diagnosed with cancer in Austria; 40,000 of them are newly diagnosed every year. Around 20,000 people, which corresponds to a quarter of all deaths per year, die from their tumour disease. Due to the general increase in life expectancy, but also improved screening and diagnostic methods, these numbers will increase considerably in the coming years. In fact, the incidence of cancer has increased by 35% in the period from 2006 to 2016. At the same time, however, cancer survival rates have improved, further increasing the number of people living with cancer. For these reasons, tumour diseases are of the highest relevance to health policy.

Objective of the Molecular Oncology and Haematology Working Group

On the one hand, the aim of the scientific working group is to advance the understanding of the epidemiology and prognosis of specific tumour diseases. On the other hand, the research of molecular basics of oncological/haematological tumour diseases and the development of new diagnostics, therapeutics and innovative therapy strategies derived from them are in the foreground.

Your support 

Even small contributions help to purchase necessary consumables (chemicals, antibodies, assay kits, plasticware) and thus advance the progress of oncological/haematological research for the benefit of our tumour patients.

Your donation to KL

Are you interested in supporting the Molecular Oncology and Haematology Working Group?

Please contact us, we will be happy to provide you with further information.

Mag. (FH) Ingrid Brunner

Mag. (FH) Ingrid Brunner

Communications, PR and Marketing

OA Univ.-Prof. Mag. DDr. Klaus Podar

OA Univ.-Prof. Mag. DDr. Klaus Podar

Head of
Division of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)